What question did this study set out to answer?

This analysis aims to compare the survival and early clinical outcomes of 7+3 and azacitidine plus venetoclax in patients with CML transformed to AML.

May 29, 2026Journal of Clinical Oncology

Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

View Full Paper

Ask AI

Bookmark

Authors

MBMuhammad Mujtaba BhinderCharleston Area Medical Center HSHaris SohailCharleston Area Medical Center JCJ CollinsCharleston Area Medical Center

Discussion

Member takes

Implication

Randomized trial compares survival and early outcomes of 7+3 and aza-ven in CML transformed to AML, suggesting similar efficacy despite patient frailty.

Key Points

This analysis aims to compare the survival and early clinical outcomes of 7+3 and azacitidine plus venetoclax in patients with CML transformed to AML.
Identified adult patients with CML transformed to AML using the TriNetX Research Network.
Compared outcomes from patients receiving either 7+3 or azacitidine plus venetoclax from January 1, 2010, to June 1, 2025.
Evaluated survival using Kaplan–Meier analysis and compared early outcomes using z-tests.
One-year overall survival was 66.2% for 7+3 and 68.1% for aza-ven, with an HR of 1.03 (95% CI 0.62–1.72; p=0.91).
Early infectious complications occurred in 53.2% of patients receiving 7+3 and 58.6% receiving aza-ven; p=0.46.
Hospitalization rates within 30 days were lower with 7+3 (71.6%) compared to aza-ven (84.5%); p=0.046.

Cite This Study

Bhinder et al. (2026) studied this question.

synapsesocial.com/papers/6a192e4efab5b468c4417522 https://doi.org/10.1200/jco.2026.44.16_suppl.6579

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial compares survival and early outcomes of 7+3 and aza-ven in CML transformed to AML, suggesting similar efficacy despite patient frailty.

Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider